Research Horizons
In NEJM: Dose Escalation Best Approach for Sickle Cell Med in Africa
Post Date: June 25, 2020 | Publish Date: June 25, 2020
Russell Ware, MD, PhD
“The study shows clearly that the optimized dosing strategy for hydroxyurea, though it requires more effort than a fixed-dose treatment regimen, results in far better outcomes for children with sickle cell anemia,”
— Russell Ware, MD, PhD
Publication Information
| Original Title: | Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa |
|---|---|
| Published in: | New England Journal of Medicine |
| Publish date: | June 25, 2020 |
Research Areas
- > Asthma and Allergy
- > Autoimmune Disorders
- > Big Data and Analytics
- > Cancer
- > Community Health
- > Diabetes and Obesity
- > Digestive System
- > Emergency and Critical Care
- > Genomics and Development
- > Health Inequities
- > Heart and Lung
- > Imaging Sciences
- > Infectious Diseases and Vaccines
- > Mind Brain Behavior
- > Organoids
- > Ortho, Sports Med and Rehab
- > Perinatal
- > Quality and Safety
- > Rare Diseases
- > Sensory Systems
- > Surgical Science
- > Tools for Science
Latest Posts
About this blog
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.
Blog Archive
- > June 2021
- > May 2021
- > April 2021
- > March 2021
- > February 2021
- > January 2021
- > December 2020
- > November 2020
- > October 2020
- > September 2020
- > August 2020
- > July 2020
- > June 2020
- > May 2020
- > April 2020
- > March 2020
- > February 2020
- > January 2020
- > December 2019
- > November 2019
- > October 2019
- > September 2019
- > August 2019
- > July 2019
- > June 2019